<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05089318</url>
  </required_header>
  <id_info>
    <org_study_id>FLEXOPAM</org_study_id>
    <nct_id>NCT05089318</nct_id>
  </id_info>
  <brief_title>Evaluation of Flexofytol® PLUS in Hand Osteoarthritis.</brief_title>
  <official_title>Curcuminoids and Boswellia Serrata Extracts Combination Decreases Hand Osteoarthritis Symptoms : Results From a Belgian Real-Life Experience</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tilman S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tilman S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of curcuminoids and Boswellia serrata&#xD;
      extracts combination (Flexofytol PLUS) during a 12-weeks period in hand ostearthritis&#xD;
      patients on the evaluation of pain.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Actual">September 1, 2021</completion_date>
  <primary_completion_date type="Actual">September 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pain using a Visual Analog Scale (VAS)</measure>
    <time_frame>84 days</time_frame>
    <description>Change from baseline of the mean pain over the last 48 hours by the patient</description>
  </primary_outcome>
  <enrollment type="Actual">239</enrollment>
  <condition>Hand Osteoarthritis</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Flexofytol PLUS</intervention_name>
    <description>2 tablets in the morning and in the evening for minimum 6 weeks.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  Older dan 45 years old,&#xD;
&#xD;
          -  With hand ostheorthritis,&#xD;
&#xD;
          -  Regularly uses of paracetamol or NSAIDs to manage pain,&#xD;
&#xD;
          -  Painful symptoms must have been present for more than 6 months,&#xD;
&#xD;
          -  The patient assesses their pain on a visual pain scale and must be greater than 4 out&#xD;
             of 10 over the last 48 hours.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Older dan 45 years old,&#xD;
&#xD;
          -  With hand ostheorthritis,&#xD;
&#xD;
          -  Regularly uses of paracetamol or NSAIDs to manage pain,&#xD;
&#xD;
          -  Painful symptoms must have been present for more than 6 months,&#xD;
&#xD;
          -  The patient assesses their pain on a visual pain scale and must be greater than 4 out&#xD;
             of 10 over the last 48 hours.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Related to previous and associated treatments:&#xD;
&#xD;
               -  Corticosteroids injection in the 3 previous months, whatever the joint concerned,&#xD;
&#xD;
               -  Use of Slow-acting drugs for OA and/or dietary supplements taken within less than&#xD;
                  6 months prior to the study(ex: chondroitin sulfate, diacerein, soy and avocado&#xD;
                  unsaponifiables, oxaceprol, granions de cuivre, glucosamine, phytotherapy for OA,&#xD;
                  homeopathy for OA...),&#xD;
&#xD;
               -  Anticoagulant (coumarinic) treatment and heparin,&#xD;
&#xD;
               -  General corticotherapy in the 3 previous months,&#xD;
&#xD;
               -  Contraindication to paracetamol, curcumin, boswellia and NSAID's.&#xD;
&#xD;
          -  Related to associated pathologies:&#xD;
&#xD;
               -  Patient suffering from serious associated illness (liver failure, kidney failure,&#xD;
                  non-controlled cardiovascular diseases...),&#xD;
&#xD;
               -  The patient has rheumatoid arthritis or gout,&#xD;
&#xD;
               -  The patient has a bile obstruction.&#xD;
&#xD;
          -  Related to patient:&#xD;
&#xD;
               -  Pregnant or breastfeeding women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yvan Dierckxsens</last_name>
    <role>Study Director</role>
    <affiliation>Tilman S.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yves Henrotin</name>
      <address>
        <city>Boncelles</city>
        <state>Liège</state>
        <zip>4100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yves Henrotin</name>
      <address>
        <city>Boncelles</city>
        <zip>4100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 11, 2021</study_first_submitted>
  <study_first_submitted_qc>October 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoarthritis</keyword>
  <keyword>curcumin</keyword>
  <keyword>boswellia serrata</keyword>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

